HLB PANAGENE Co., LTD. (KOSDAQ:046210)

Market Cap	76.26B
Revenue (ttm)	14.51B
Net Income (ttm)	1.77B
Shares Out	45.13M
EPS (ttm)	40.45
PE Ratio	41.78
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,209
Average Volume	79,004
Open	1,710.00
Previous Close	1,707.00
Day's Range	1,615.00 - 1,758.00
52-Week Range	1,591.00 - 3,330.00
Beta	0.12
RSI	47.45
Earnings Date	Nov 14, 2025

About HLB PANAGENE Co., LTD.

HLB PANAGENE Co., LTD. develops products in the field of molecular diagnostics in South Korea. Its products include liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug resistance diseases; and peptide nucleic acid products. The co...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1976
• Employees: 82
• Stock Exchange: KOSDAQ
• Ticker Symbol: 046210

Financial Performance

In 2024, HLB PANAGENE Co., LTD.'s revenue was 13.20 billion, an increase of 7.71% compared to the previous year's 12.25 billion. Losses were -1.94 billion, -59.63% less than in 2023.